Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 17/20 | 0.61 |
| ▸ | FNTB | P49356 | 17/20 | 0.61 |
| ▸ | HRAS | P01112 | 1/20 | 0.61 |
| ▸ | KRAS | P01116 | 1/20 | 0.61 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21877258 | 1.00 | FNTA (0.61) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL18041271 | 1.00 | FNTA (0.61) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL29171479 | 0.89 | FNTA (0.46) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL29171480 | 0.89 | FNTA (0.46) | FNTAFNTBHRASKRASPGGT1B | |
| Bms-214662 SCHEMBL16499911 | 0.76 | FNTA (1.00) | FNTAFNTBHRASKRASPGGT1B | |
| Bms-214662 SCHEMBL94663 | 0.76 | FNTA (1.00) | FNTAFNTBHRASKRASPGGT1B | |
| Bms-214662 SCHEMBL30498791 | 0.75 | FNTA (0.99) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL7685754 | 0.75 | FNTA (0.43) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL7685758 | 0.75 | FNTA (0.43) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL22050803 | 0.73 | FNTA (0.86) | FNTAFNTBHRASKRASPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200129489-A1 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | DECIPHERA PHARMACEUTICALS, LLC | 2020-04-30 | — | — | US | claimed |
| US-20160256448-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | claimed |
| US-20160256458-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | claimed |
| US-12616683-B2 | Combination therapy for the treatment of gastrointestinal stromal tumors | DECIPHERA PHARMACEUTICALS, LLC (US) | 2026-05-05 | — | — | US | disclosed |
| EP-3746059-B1 | COMBINATION THERAPY FOR THE TREATMENT OF GASTROINTESTINAL STROMAL TUMORS | DECIPHERA PHARMACEUTICALS LLC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20250387380-A1 | AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2025-12-25 | — | — | US | disclosed |
| US-12485131-B2 | Formulations of brincidofovir | EMERGENT BIODEFENSE OPERATIONS LANSING LLC (US) | 2025-12-02 | — | — | US | disclosed |
| EP-3474822-B1 | FORMULATIONS OF BRINCIDOFOVIR | EMERGENT BIODEFENSE OPERATIONS LANSING LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-12318374-B2 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-06-03 | — | — | US | disclosed |
| CN-119970649-A | Amorphous kinase inhibitor formulations and methods of use thereof | 德西费拉制药有限责任公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119950433-A | Amorphous kinase inhibitor formulations and methods of use thereof | 德西费拉制药有限责任公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20210196693-A1 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREA | DECIPHERA PHARMACEUTICALS, LLC | 2021-07-01 | — | — | US | disclosed |
| US-20210145805-A1 | COMBINATION THERAPY FOR THE TREATMENT OF GASTROINTESTINAL STROMAL TUMOR | DECIPHERA PHARMACEUTICALS, LLC | 2021-05-20 | — | — | US | disclosed |
| US-20210015801-A1 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | DECIPHERA PHARMACEUTICALS, LLC | 2021-01-21 | — | — | US | disclosed |
| CN-111818915-A | Combination therapy for treating gastrointestinal stromal tumors | 德西费拉制药有限责任公司 | 2020-10-23 | — | — | CN | disclosed |
| CN-111328283-A | Use of 1- [ 4-bromo-5- [ 1-ethyl-7- (methylamino) -2-oxo-1, 2-dihydro-1, 6-naphthyridin-3-yl ] -2-fluorophenyl ] -3-phenylurea and analogs for the treatment of cancer associated with genetic abnormalities in platelet-derived growth factor receptor α | 德西费拉制药有限责任公司 | 2020-06-23 | — | — | CN | disclosed |
| US-20200129489-A1 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | DECIPHERA PHARMACEUTICALS, LLC | 2020-04-30 | — | — | US | disclosed |
| US-20170368082-A1 | FORMULATIONS OF BRINCIDOFOVIR | SYMBIO PHARMACEUTICALS LIMITED (JP) | 2017-12-28 | — | — | US | disclosed |
| US-20160256458-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160256448-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160256448-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | FNTA 4430/4885FNTB 3394/4885HRAS 770/4885 |
| US-20210145805-A1 | COMBINATION THERAPY FOR THE TREATMENT OF GASTROINTESTINAL STROMAL TUMOR | MAPKAPK2, MAPKAP1, MAPK13 | FNTA 4373/4885FNTB 3484/4885HRAS 46/4885 |
| US-12318374-B2 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | PDGFRA, PDGFRB, KIT | FNTA 4085/4885FNTB 2820/4885HRAS 321/4885 |
| US-20160256458-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRPF3, BRD7 | FNTA 4551/4885FNTB 3656/4885HRAS 1171/4885 |
| US-20250387380-A1 | AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF | KIT, CSNK1D, STK17A | FNTA 4750/4885FNTB 4658/4885HRAS 1286/4885 |
| US-20170368082-A1 | FORMULATIONS OF BRINCIDOFOVIR | SAMHD1, UGT2B7, HPRT1 | FNTA 329/4885FNTB 1761/4885HRAS 428/4885 |
| US-20200129489-A1 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | PDGFRA, PDGFRB, ALK | FNTA 3530/4885FNTB 2759/4885HRAS 32/4885 |
| US-12485131-B2 | Formulations of brincidofovir | SAMHD1, UGT2B7, HPRT1 | FNTA 329/4885FNTB 1761/4885HRAS 428/4885 |
| US-12616683-B2 | Combination therapy for the treatment of gastrointestinal stromal tumors | KIT, ABL1, MAP2K7 | FNTA 4613/4885FNTB 3476/4885HRAS 456/4885 |
| US-20210196693-A1 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREA | PDGFRA, PDGFRB, KIT | FNTA 4183/4885FNTB 2817/4885HRAS 210/4885 |
| US-20210015801-A1 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | PDGFRA, PDGFRB, ALK | FNTA 3530/4885FNTB 2759/4885HRAS 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.